Plus Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Plus Therapeutics, Inc. (PSTV) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-12.98-13.32-20.28-13.40-8.24
Depreciation & Amortization0.720.630.710.420.37
Stock Based Compensation0.550.570.610.610.25
Change in Working Capital3.22-1.125.601.240.12
Change in Accounts Receivable-0.570.000.000.001.17
Change in Accounts Payable4.70-3.686.451.73-1.23
Change in Other Working Capital-0.912.28-2.50-0.500.18
Other Operating Activities-2.070.080.00-0.01-2.29
Net Cash from Operating Activities-10.55-12.85-12.97-10.28-8.43
Investing Activities
Capital Expenditures-0.15-0.16-0.51-0.14-0.09
Purchases of Investments-15.590.000.000.000.00
Sales/Maturities of Investments12.170.00-0.250.00-0.40
Other Investing Activities-0.550.000.000.000.00
Net Cash from Investing Activities-4.11-0.16-0.76-0.08-0.49
Financing Activities
Debt Repayment-0.70-1.61-1.61-0.280.00
Common Stock Issued7.275.5315.8320.695.11
Common Stock Repurchased-0.37-0.130.000.000.00
Other Financing Activities0.00-0.35-0.770.000.00
Net Cash from Financing Activities6.193.4513.4520.42-0.32
Summary
Net Change in Cash-8.48-9.57-0.2810.05-9.25
Cash at Beginning of Period8.5518.1218.408.350.00
Cash at End of Period0.088.5518.1218.400.00
Free Cash Flow-10.70-13.01-13.48-10.42-8.53
Supplemental Disclosures
Interest Paid0.030.220.330.390.57